331
Participants
Start Date
October 30, 2019
Primary Completion Date
April 30, 2024
Study Completion Date
April 30, 2024
Tildrakizumab
The study physicians will choose the treatment independently of the enrolment in the study according to routine care.
Investigator Site 1, Vienna
Investigational site 5, Augsburg
Investigational site 10, Berlin
Investigational site 11, Berlin
Investigational site 13, Berlin
Investigational site 8, Erlangen
Investigational site 9, Greifswald
Investigational site 1, Hamburg
Investigational site 2, Hamburg
Investigational site 7, Kiel
Investigational site 3, Lübeck
Investigational site 6, München
Investigational site 12, Oberursel
Investigational site 4, Quedlinburg
Investigational site 6, Catania
Investigational site 7, Genova
Investigational site 3, Modena
Investigational site 4, Parma
Investigational site 1, Roma
Investigational site 2, Roma
Investigational site 5, Roma
Investigational site 1, Breda
Lead Sponsor
Almirall, S.A.
INDUSTRY